CL2020002188A1 - Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico. - Google Patents
Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.Info
- Publication number
- CL2020002188A1 CL2020002188A1 CL2020002188A CL2020002188A CL2020002188A1 CL 2020002188 A1 CL2020002188 A1 CL 2020002188A1 CL 2020002188 A CL2020002188 A CL 2020002188A CL 2020002188 A CL2020002188 A CL 2020002188A CL 2020002188 A1 CL2020002188 A1 CL 2020002188A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydrotriazinone
- dihydropyrimidinone
- pharmaceutical use
- saturated rings
- compounds fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados, o sales farmacéuticamente aceptables de los mismos, que tienen actividad antagonista de RORγ, composiciones farmacéuticas que los comprenden, y uso farmacéutico de los mismos; se proporciona un compuesto de fórmula [I] o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende y el uso farmacéutico del mismo;
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018035601 | 2018-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002188A1 true CL2020002188A1 (es) | 2020-12-18 |
Family
ID=67805013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002188A CL2020002188A1 (es) | 2018-02-28 | 2020-08-25 | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20190300490A1 (es) |
| EP (1) | EP3760619B1 (es) |
| JP (1) | JP7200005B2 (es) |
| KR (1) | KR20200127177A (es) |
| CN (1) | CN111741948B (es) |
| AR (1) | AR123121A1 (es) |
| AU (1) | AU2019228916A1 (es) |
| BR (1) | BR112020016784A2 (es) |
| CA (1) | CA3088000A1 (es) |
| CL (1) | CL2020002188A1 (es) |
| IL (1) | IL276326A (es) |
| MX (1) | MX2020008929A (es) |
| PE (1) | PE20210447A1 (es) |
| PH (1) | PH12020551342A1 (es) |
| RU (1) | RU2020131405A (es) |
| SG (1) | SG11202007119UA (es) |
| TW (1) | TW202000652A (es) |
| WO (1) | WO2019167982A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912715B2 (en) | 2016-08-29 | 2024-02-27 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200127177A (ko) | 2018-02-28 | 2020-11-10 | 니뽄 다바코 산교 가부시키가이샤 | 포화 환 축합 디히드로피리미디논 또는 디히드로트리아지논 화합물 및 그의 의약 용도 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR054617A1 (es) | 2005-06-14 | 2007-07-04 | Schering Corp | Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden |
| KR20100037053A (ko) | 2007-06-01 | 2010-04-08 | 쉐링 코포레이션 | 감마 세크레타제 조절인자 |
| AU2009239536C1 (en) * | 2008-04-22 | 2012-12-13 | Merck Sharp & Dohme Corp. | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
| WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
| US10047098B2 (en) | 2014-11-25 | 2018-08-14 | Merck Sharp & Dohme Corp. | C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use |
| EP3231793B1 (en) * | 2014-12-12 | 2020-03-11 | Japan Tobacco Inc. | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| KR20200127177A (ko) | 2018-02-28 | 2020-11-10 | 니뽄 다바코 산교 가부시키가이샤 | 포화 환 축합 디히드로피리미디논 또는 디히드로트리아지논 화합물 및 그의 의약 용도 |
-
2019
- 2019-02-27 KR KR1020207024427A patent/KR20200127177A/ko not_active Application Discontinuation
- 2019-02-27 AU AU2019228916A patent/AU2019228916A1/en not_active Abandoned
- 2019-02-27 JP JP2019033423A patent/JP7200005B2/ja active Active
- 2019-02-27 RU RU2020131405A patent/RU2020131405A/ru unknown
- 2019-02-27 BR BR112020016784-3A patent/BR112020016784A2/pt not_active Application Discontinuation
- 2019-02-27 AR ARP190100481A patent/AR123121A1/es not_active Application Discontinuation
- 2019-02-27 WO PCT/JP2019/007435 patent/WO2019167982A1/ja unknown
- 2019-02-27 CN CN201980015796.9A patent/CN111741948B/zh active Active
- 2019-02-27 TW TW108106804A patent/TW202000652A/zh unknown
- 2019-02-27 MX MX2020008929A patent/MX2020008929A/es unknown
- 2019-02-27 SG SG11202007119UA patent/SG11202007119UA/en unknown
- 2019-02-27 US US16/287,871 patent/US20190300490A1/en not_active Abandoned
- 2019-02-27 PE PE2020001290A patent/PE20210447A1/es unknown
- 2019-02-27 CA CA3088000A patent/CA3088000A1/en active Pending
- 2019-02-27 EP EP19761273.2A patent/EP3760619B1/en active Active
-
2020
- 2020-07-27 IL IL276326A patent/IL276326A/en unknown
- 2020-08-25 CL CL2020002188A patent/CL2020002188A1/es unknown
- 2020-08-27 PH PH12020551342A patent/PH12020551342A1/en unknown
-
2021
- 2021-05-28 US US17/334,517 patent/US11834421B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912715B2 (en) | 2016-08-29 | 2024-02-27 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019167982A1 (ja) | 2019-09-06 |
| PE20210447A1 (es) | 2021-03-08 |
| US20190300490A1 (en) | 2019-10-03 |
| RU2020131405A (ru) | 2022-03-24 |
| CA3088000A1 (en) | 2019-09-06 |
| BR112020016784A2 (pt) | 2021-01-12 |
| CN111741948A (zh) | 2020-10-02 |
| IL276326A (en) | 2020-09-30 |
| AU2019228916A1 (en) | 2020-07-02 |
| KR20200127177A (ko) | 2020-11-10 |
| EP3760619A1 (en) | 2021-01-06 |
| AR123121A1 (es) | 2022-11-02 |
| SG11202007119UA (en) | 2020-08-28 |
| JP7200005B2 (ja) | 2023-01-06 |
| US11834421B2 (en) | 2023-12-05 |
| PH12020551342A1 (en) | 2021-06-21 |
| TW202000652A (zh) | 2020-01-01 |
| EP3760619A4 (en) | 2021-07-07 |
| CN111741948B (zh) | 2023-11-10 |
| MX2020008929A (es) | 2020-10-01 |
| US20220119355A1 (en) | 2022-04-21 |
| EP3760619B1 (en) | 2023-10-25 |
| JP2019151624A (ja) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002188A1 (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico. | |
| CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| CL2021002165A1 (es) | Nuevos derivados de compuestos heterociclicos y uso de los mismos | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| EA202091256A1 (ru) | Новые антагонисты рецептора брадикинина | |
| CO2020011860A2 (es) | Compuestos de 4–metildihidropirimidinona y su uso farmacéutico | |
| CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| BR112020008258B8 (pt) | Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido) | |
| CU20190029A7 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| MX2020004810A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| BR112017020081A2 (pt) | análogos deuterados de etifoxina, seus derivados e usos dos mesmos | |
| UY36124A (es) | Derivados de carboxamida | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| CO2022004978A2 (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| UY35209A (es) | Compuestos tricíclicos | |
| CL2023000387A1 (es) | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
| UY37412A (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos |